Patient satisfaction with rizatriptan versus other triptans: Direct head-to-head comparisons

International Journal of Clinical Practice

Volumn 55, Issue 8, 2001, Pages 552-556

  Gerth, W C ^a,b   McCarroll, K A ^a,b   Santanello, N C ^a,b   Vandormael, K ^a,b   Zhang, Q ^a,b   Man Nix, L K ^a,b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Headache Wellness Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NARATRIPTAN; PLACEBO; RIZATRIPTAN; SUMATRIPTAN; ZOLMITRIPTAN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; PATIENT SATISFACTION; PRIORITY JOURNAL; RATING SCALE;

ADOLESCENT; ADULT; AGED; CLINICAL TRIALS, PHASE III; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; PATIENT SATISFACTION; SEROTONIN AGONISTS; SUMATRIPTAN; TRIAZOLES; TRYPTAMINES;

EID: 0034757639     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Lipton RB.Stewart WF. The epidemiology of migraine. Eur Neurol 1994: 34(suppI2): 6-11.
2. Rasmussen BK, Diesen J, Classification and symptoms: drug treatment of migraine and other headaches. Monographs in Clinical Neuroscience, vol 17. Basel: S Karger AG, 2000.
3. Solomon GD, Santanello NC. Impact of migraine and migraine therapy on productivity and quality of life. Neurology 2000; 5S(suppl 2): S29-S35.
4. International Headache Society. Members' handbook 2000. Oslo: Scandinavian University Press, 1999.
5. Tfelt-Hansen P, Teall J, Rodriquez F et al. Oral rizatriptan versus oral sumatriptan: a randomized, comparative study in the acute treatment of migraine. Headache 1998; 38: 748-755.
6. Kramer MS, Matzura-Wolfe D, Polis A et al. A placebo-controlled crossover study of rizatriptan in the treatment of multiple migraine attacks. Neurology 1998; 51: 773-781.
7. Block GA. Goldstein J, Polis A et al. Efficacy and safety of rizatriptan versus standard care during long-term treatment for migraine. Headache 1998;38: 764-771.
8. Davies GM. Santanello NC, Lipton R. Determinants of patient satisfaction with migraine therapy. Cephalalgia 2000; 20: 554-560.
9. Goldstein J, Ryan R. Jiang K et al. Crossover comparison of rizatriptan 5 mg and 10 mg versus sumatriptan 25 mg and 50 mg in migraine. Headache 1998; 38: 737-747.
10. Pascual J, Vega P, Diener H-C et al. Comparison of rizatriptan 10 mg vs zolmitriptan 2.5 mg in the acute treatment of migraine. Cephalalgia 2000; 20: 455-461.
11. Bomhof M, Paz J, Legg N et al. Comparison of rizatriptan 10 mg vs naratriptan 2.5 mg in migraine. Eur Neural 1999; 42: 173-179.
12. Adelman J, Lipton RB, Ferrari MD et al. Freedom from pain and associated symptoms at 2h: comparison of rizatriptan and other triptans [Abstract]. Cephalalgia 2000; 20: 344-345.
13. Santanello NC, Davies GM, Alien C et al. Determinants of migrainespecific quality of life. Poster presentation at American Association for the Study of Headache, San Francisco, California, June 26-28, 1998.
14. Bayliss MS, Black LK, Malik F, Ware JE. Patient satisfaction with migraine therapy: naratriptan compared to customary therapy. Abstract for Headache World 2000. Cephalalgia 2000; 20: 411.
15. Powers C, Szeto S, Pangtay D et al. Evaluation of migraineurs' preference for naratriptan over conventional first-line agents. Arch Fam Med 2000; 9: 753-757.
16. Cohen JA, Beall D, Beck A et al. Sumatriptan treatment for migraine in a health maintenance organization: economic, humanistic, and clinical outcomes, din Therapeut 1999; 21(1): 190-204.
17. Solomon S.Frishberg B.HuXH et al. Improved migraine treatment outcomes with rizatriptan in triptan naive patients [abstract]. Final programme 42nd Annual Scientific Meeting of the American Headache Society 2000.